ARRY
Price
$4.56
Change
+$0.23 (+5.31%)
Updated
Apr 24 closing price
Capitalization
2.22B
11 days until earnings call
CHRS
Price
$1.01
Change
-$0.10 (-9.01%)
Updated
Apr 24 closing price
Capitalization
117.06M
13 days until earnings call
Ad is loading...

ARRY vs CHRS

Header iconARRY vs CHRS Comparison
Open Charts ARRY vs CHRSBanner chart's image
Array Technologies
Price$4.56
Change+$0.23 (+5.31%)
Volume$4.04M
Capitalization2.22B
Coherus BioSciences
Price$1.01
Change-$0.10 (-9.01%)
Volume$2.1M
Capitalization117.06M
ARRY vs CHRS Comparison Chart
Loading...
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARRY vs. CHRS commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Buy and CHRS is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CHRS: $1.01)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green while.

  • CHRS’s FA Score: 0 green, 5 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARRY’s TA Score shows that 5 TA indicator(s) are bullish while CHRS’s TA Score has 5 bullish TA indicator(s).

  • ARRY’s TA Score: 5 bullish, 3 bearish.
  • CHRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ARRY is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -9.82% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARRY($2.22B) has a higher market cap than CHRS($117M). ARRY has higher P/E ratio than CHRS: ARRY (26.23) vs CHRS (4.04). ARRY YTD gains are higher at: -24.503 vs. CHRS (-26.812). ARRY has higher annual earnings (EBITDA): 276M vs. CHRS (37.3M). ARRY has more cash in the bank: 249M vs. CHRS (97.7M). CHRS has less debt than ARRY: CHRS (270M) vs ARRY (730M). ARRY has higher revenues than CHRS: ARRY (1.58B) vs CHRS (304M).
ARRYCHRSARRY / CHRS
Capitalization2.22B117M1,899%
EBITDA276M37.3M740%
Gain YTD-24.503-26.81291%
P/E Ratio26.234.04649%
Revenue1.58B304M519%
Total Cash249M97.7M255%
Total Debt730M270M270%
FUNDAMENTALS RATINGS
ARRY vs CHRS: Fundamental Ratings
ARRY
CHRS
OUTLOOK RATING
1..100
1119
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9146
P/E GROWTH RATING
1..100
2349
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (90) in the Biotechnology industry is in the same range as ARRY (98). This means that CHRS’s stock grew similarly to ARRY’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARRY (100). This means that CHRS’s stock grew similarly to ARRY’s over the last 12 months.

ARRY's SMR Rating (99) in the Biotechnology industry is in the same range as CHRS (100). This means that ARRY’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for ARRY (91). This means that CHRS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ARRY's P/E Growth Rating (23) in the Biotechnology industry is in the same range as CHRS (49). This means that ARRY’s stock grew similarly to CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARRYCHRS
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 22 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GOTRF1.240.10
+9.11%
Goliath Resources Ltd.
ASMVY19.410.34
+1.76%
ASMPT LTD.
NPNYY6.660.06
+0.91%
Nippon Yusen Kabushiki Kaisha
TRSSX22.56N/A
N/A
T. Rowe Price Instl Small-Cap Stock
EVSRX22.06N/A
N/A
Allspring Disciplined US Core R6

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ADCT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-9.01%
ADCT - CHRS
39%
Loosely correlated
+5.43%
ARRY - CHRS
39%
Loosely correlated
+5.31%
AXON - CHRS
38%
Loosely correlated
+2.39%
XENE - CHRS
35%
Loosely correlated
+1.62%
AMRN - CHRS
35%
Loosely correlated
+7.92%
More